Shah, Amil M. http://orcid.org/0000-0003-1056-4451
Myhre, Peder L.
Arthur, Victoria http://orcid.org/0000-0003-2760-5053
Dorbala, Pranav
Rasheed, Humaira http://orcid.org/0000-0002-3331-5864
Buckley, Leo F.
Claggett, Brian
Liu, Guning
Ma, Jianzhong
Nguyen, Ngoc Quynh
Matsushita, Kunihiro
Ndumele, Chiadi
Tin, Adrienne http://orcid.org/0000-0002-4207-5866
Hveem, Kristian
Jonasson, Christian http://orcid.org/0000-0002-7694-6025
Dalen, Håvard
Boerwinkle, Eric
Hoogeveen, Ron C.
Ballantyne, Christie http://orcid.org/0000-0002-6432-1730
Coresh, Josef http://orcid.org/0000-0002-4598-0669
Omland, Torbjørn
Yu, Bing http://orcid.org/0000-0003-4818-1077
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL148218)
Article History
Received: 2 March 2023
Accepted: 21 December 2023
First Online: 15 January 2024
Competing interests
: The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract nos. (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700005I, HHSN268201700004I). Dr Shah was supported by NIH/NHLBI grants R01HL135008, R01HL143224, R01HL150342, R01HL148218, R01HL160025, and K24HL152008. Drs Myhre and Omland were supported by Research Council of Norway grant 296357/TOE. Dr Buckley was supported by NIH/NHLBI grant K23HL150311. Dr. Ballantyne was supported by NIH/NHLBI grant R01HL134320. Dr. Yu was in part supported by R01HL148218, R01 HL160793 and the JLH Foundation. The funder had no role design and conduct of this study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Dr. Shah reports research support from Novartis through Brigham and Women’s Hospital and consulting fees from Philips Ultrasound and Janssen. Dr. Myhre has consulted for and/or received speaker honoraria from Amarin, AmGen, Bayer, AstraZeneca, Boehringer-Ingelheim, Novartis, Novo Nordisk, Pharmacosmos, and Us2.ai. Dr Dalen holds positions at Centre for Innovative Ultrasound Solutions (CIUS) and Precision Health Center for optimized cardiac care (ProCardio) - both Norwegian Research Council (NRC) centers for research-based innovation, where GE Healthcare, Horten, Norway is one of the institutional partners, has research contracts with GE Healthcare, and acts as research advisor for Boehringer Ingelheim. Dr. Hoogeveen reports research support from Denka Seiken through Baylor College of Medicine and consulting fees from Denka Seiken. Dr Ballantyne reports grant/research support from Abbott Diagnostic, Akcea, Amgen, Arrowhead, Esperion, Ionis, Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, NIH, AHA, and ADA, and is a consultant for 89Bio, Abbott Diagnostics, Alnylam Pharmaceuticals, Althera, Amarin, Amgen, Arrowhead, Astra Zeneca, Denka Seiken, Esperion, Genentech, Gilead, Illumina, Ionis, Matinas BioPharma Inc, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic. Dr. Coresh is a scientific advisor to Soma Logic. The remaining authors report no competing interests.